Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Bleomycin-induced pulmonary fibrosis"'
Publikováno v:
Biomedical Journal, Vol 47, Iss 6, Pp 100720- (2024)
Background: Pulmonary fibrosis is a progressive diffuse parenchymal lung disorder with a high mortality rate. Studies have indicated that injured lung tissues release various pro-inflammatory factors, and produce a large amount of nitric oxide. There
Externí odkaz:
https://doaj.org/article/b20d2047aa83402dae261099284843c5
Autor:
Zeena A. Hussein, Ahmed R. Abu-Raghif, Nibras J. Tahseen, Khalid A. Rashed, Nada S. Shaker, Hayder Adnan Fawzi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-21 (2024)
Abstract This study aimed to investigate the potential anti-fibrotic activity of vinpocetine in an experimental model of pulmonary fibrosis by bleomycin and in the MRC-5 cell line. Pulmonary fibrosis was induced in BALB/c mice by oropharyngeal aspira
Externí odkaz:
https://doaj.org/article/1c20b8a8bfee44e2b090e90ca394bc35
Autor:
Xinglong Liu, Liang Zeng, Yuchuan Zhou, Xinrui Zhao, Lin Zhu, Jianghong Zhang, Yan Pan, Chunlin Shao, Jiamei Fu
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-19 (2023)
Abstract Background Interstitial lung diseases (ILDs) can be induced and even exacerbated by radiotherapy in thoracic cancer patients. The roles of immune responses underlying the development of these severe lung injuries are still obscure and need t
Externí odkaz:
https://doaj.org/article/3395d99be1e542c789069ffaa41b7efa
Autor:
Qingsong Li, Yue Wang, Liu Ji, Jianhan He, Haixia Liu, Weizhen Xue, Huihui Yue, Ruihan Dong, Xin Liu, Daqing Wang, Huilan Zhang
Publikováno v:
Heliyon, Vol 9, Iss 12, Pp e22461- (2023)
The bleomycin-induced pulmonary fibrosis mouse model is commonly used in idiopathic pulmonary fibrosis research, but its cellular and molecular changes and efficiency as a model at the molecular level are not fully understood. In this study, we used
Externí odkaz:
https://doaj.org/article/4e64e6d489a849e692790bde3538cf8c
Autor:
Katherine E. Stephenson, Joanne Porte, Aoife Kelly, William A. Wallace, Catherine E. Huntington, Catherine L. Overed-Sayer, E. Suzanne Cohen, R. Gisli Jenkins, Alison E. John
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease (ILD) with limited treatment options. Interleukin-33 (IL-33) is proposed to play a role in the development of IPF however the exclusive use of prophyla
Externí odkaz:
https://doaj.org/article/75bb0ba23cf7458cbe360a62e4dff65c
Autor:
Yang Miao, Yanhua Wang, Zhun Bi, Kai Huang, Jingjing Gao, Xiaohe Li, Shimeng Li, Luqing Wei, Honggang Zhou, Cheng Yang
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by alveolar epithelial cell injury and lung fibroblast overactivation. At present, only two drugs are approved by the FDA for the treatment
Externí odkaz:
https://doaj.org/article/877d1d3af1684284b7ea65d76717d765
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Heliyon, Vol 9, Iss 3, Pp e13598- (2023)
Background and aims: Idiopathic pulmonary fibrosis (IPF) is a fibrosing lung disease with unknown etiology, leading to cough and dyspnoea, which is also one of the most common sequelae affecting the quality of life of COVID-19 survivors. There is no
Externí odkaz:
https://doaj.org/article/21da4b67b97a4db6bd2a23a2936ab729